Statements (44)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Zyprexa
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
gptkb:Zyprexa
Relprevv |
| gptkbp:clinical_trial |
gptkb:unknown
short-term treatment Phase III long-term treatment |
| gptkbp:contraindication |
severe liver impairment
hypersensitivity to olanzapine |
| gptkbp:dosage_form |
solution for injection
|
| gptkbp:effective_date |
2009-09-15
|
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
long-acting injectable
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zyprexa Relprevv
|
| gptkbp:indication |
maintenance treatment of bipolar disorder
acute treatment of schizophrenia maintenance treatment of schizophrenia acute treatment of manic or mixed episodes of bipolar disorder |
| gptkbp:ingredients |
gptkb:olanzapine
C17 H20 N4 O2 S |
| gptkbp:interacts_with |
CNS depressants
antihypertensives other antipsychotics |
| gptkbp:is_atype_of |
N05 A H04
|
| gptkbp:is_used_for |
treatment of schizophrenia
treatment of bipolar disorder |
| gptkbp:lifespan |
30 hours
|
| gptkbp:manager |
intramuscular injection
|
| gptkbp:manufacturer |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:marketed_as |
gptkb:Zyprexa_Relprevv
|
| gptkbp:metabolism |
liver
|
| gptkbp:packaging |
single-dose vial
|
| gptkbp:population |
gptkb:Person
adults |
| gptkbp:side_effect |
dizziness
dry mouth weight gain sedation hyperglycemia |
| gptkbp:storage |
store at room temperature
|
| gptkbp:type_of |
144701-48-4
|